Christian Reinhardt

Prof. Dr. Christian Reinhardt is a leading oncology researcher and clinician at the University of Duisburg-Essen, serving as Director of the Clinic for Hematology and Stem Cell Transplantation at University Hospital Essen. He is a key member of the West German Cancer Centre (WTZ) and the ZMB (Zentrum für Molekulare Biomedizin), where he leads research in the Oncology program. His work bridges clinical practice and molecular cancer research, with a focus on improving outcomes for patients with aggressive lymphomas and lung cancers.

His research interests center on B-cell lymphomas, DNA damage response, transcription factor p53, functional genomics, and cellular immunotherapy. He investigates mechanisms of therapy resistance, tumor evolution, and immune evasion, particularly in the context of CAR-T therapy and stem cell transplantation. His lab employs cutting-edge genomic and functional screening approaches to identify druggable vulnerabilities in cancer.

The recent publications highlight a strong trend in understanding molecular drivers of aggressive cancers—particularly in lymphoma and small cell lung cancer. Themes include genomic instability, immune modulation, metabolic dependencies, and therapy resistance mechanisms. His work frequently appears in top journals like Nature, Cell, Blood, and Cancer Discovery, reflecting high impact and translational relevance.

His scientific honors include:

• German Cancer Award 2023 (Deutscher Krebspreis)
• DKH-Exzellenzförderprogramm funding (1 million euros until 2028)
• Lead role in the TACTIC project (11.8 million euros from German Cancer Aid)

Prof. Reinhardt leads a well-funded, dynamic research team with strong translational links to clinical oncology. He is actively recruiting MD, PhD, and postdoctoral candidates, indicating ongoing research expansion. His lab collaborates nationally and focuses on preclinical drug development, particularly targeting transcriptional addiction in cancer. He has no named students listed, but his leadership in large consortia and high-impact publications underscores his role as a principal investigator and mentor.

He is affiliated with the following institutions and initiatives:

• Faculty of Medicine, University of Duisburg-Essen
• University Hospital Essen
• West German Cancer Centre (WTZ)
• ZMB – Zentrum für Molekulare Biomedizin
• TACTIC Project (Targeting Transcriptional Addiction in Cancer)
• German Cancer Aid (Deutsche Krebshilfe) funded programs